A 28 year-old woman with Hodgkin's lymphoma…
Cancer History:
First diagnosis of cancer: 2011 Cancer type: Hodgkin’s Lymphoma nodular sclerosis, stage IIIa
First recurrence date: 01.2016 Sites: liver, abdomen, LN
Refractory or persistent disease sites: liver, abdomen, lung, LN, hepatosplenomegaly
Therapy gone through: Surgery: No
Chemotherapy 8 cycles, 4 ABVD, 4 BVD regimen, gemcitabine;
Radiotherapy: yes, post-radiatherapy pulmonary fibrosis; ABMT: 5.2016
Targeted drugs: bendamustine Immunotherapy: Brentuximab, Nivoluma others:
Clinical Trial Number: NCT02274584 (4SCAR30273); enrolled date: 18/07/2019
Interventions: 4SCAR (CD19, CD22, PSMA)
Consolidation: EIE
CRS Grade:1 ; other side effects: knee joint pain
Treatment response: PR Quality of Life: improved
Progression-free interval: 2 months
Current status: Alive with disease
Disease images before and after CART/EIE treatment (with time)
Copyright © 2016 Shenzhen Genoimmune Medical Institute all rights reserved.